How California’s 2025 ACA Marketplace Benchmark Update Changes Tier Placement for New Oral Migraine Drugs Like Zavzpret and Qulipta
Starting in 2025, California’s ACA marketplace, Covered California, will anchor its benchmark plan to the Kaiser Permanente Silver 70 HMO. That switch might sound bureaucratic, but it matters. Every carrier adjusts its formulary tiers to line up with that benchmark. For newer migraine drugs, especially the oral CGRP inhibitors, that means real changes in where they land. Patients, employers, and pharmacists will see reshuffled out-of-pocket costs and tier placements once these new tables go live.
The Meaning Behind the 2025 Benchmark Shift
The benchmark plan sets the baseline for subsidies and cost-sharing at the Silver level. In 2025, that baseline incorporates updated drug pricing, manufacturer rebate structures, and California’s statewide rebate model. CMS notes that once a benchmark shifts, marketplace plans typically recalibrate their formularies soon after. Covered California’s 2025 plan documents show new, tighter definitions for specialty tiers and clearer distinctions between preferred and non-preferred brands. Gone is some of the wiggle room carriers once had.
This shift draws a circle around emerging drug classes like calcitonin gene-related peptide (CGRP) antagonists, Zavzpret and Qulipta sit squarely inside that circle.
Oral and Nasal CGRP Inhibitors in Context
CGRP antagonists block migraine pathways by preventing activation of certain peptide receptors linked to pain signaling. Over five years, they’ve reshaped migraine treatment for patients who can’t handle triptans. But with little generic competition and high launch prices, they’ve lingered on higher-cost tiers.
| Drug Name | Generic Name | Manufacturer | FDA Approval Year | Typical 2024 Tier on Covered CA Formularies | Expected 2025 Tier Shift |
|---|---|---|---|---|---|
| Zavzpret | Zavegepant | Pfizer | 2023 | Tier 4 (Non-Preferred Brand/Specialty) | Tier 3 (Preferred Brand) |
| Qulipta | Atogepant | AbbVie | 2021 | Tier 3 (Preferred Brand) | Likely Tier 2 (Preferred Brand, lower copay) |
| Nurtec ODT | Rimegepant | Pfizer/Biohaven | 2020 | Tier 3 (Preferred Brand) | Tier 2 or maintained Tier 3 depending on rebate agreement |
The April 2024 formulary alignment guidance from Covered California now forces more consistency among carriers. Each plan must describe cost-sharing between brand tiers using percentage ranges, not fixed-dollar copays. The result: fewer arbitrary differences across insurers and clearer patient math at the pharmacy counter.
Why Migraine Drugs Are Moving Down a Tier
Both the DMHC and the Department of Insurance track plan comparability. CGRP inhibitors now have broader real-world data and steady competition, which makes insurers more willing to treat them as preferred brands. Rebate structures shifted too. AbbVie’s 2024 discount deals with CVS Caremark and OptumRx helped push Qulipta closer to Tier 2 eligibility within the ACA framework.
Zavzpret got its break another way. As the first intranasal CGRP receptor antagonist, its launch price used to land it in Tier 4. But Covered California’s new threshold, $670 per dose, places Zavzpret’s $620 product just below the “specialty” line for 2025. That triggers a likely Tier 3 reassignment. Not glamorous work, analyzing WAC thresholds, but it’s exactly how benefit design shifts happen behind the scenes.
How Tier Shifts Touch Patients
For most Silver-tier marketplace enrollees, Tier 2 drugs come with $25-$50 copays, Tier 3 runs around $65-$100, and Tier 4 invokes roughly 25% coinsurance. That difference isn’t academic. A drop from Tier 4 to Tier 3 or 2 means $45-$90 savings per fill depending on plan metal and carrier. Patients feel that faster than any public policy notice.
Pharmacies should prep for a small uptick in oral CGRP prescriptions once out-of-pocket costs fall. Benefits managers, meanwhile, will see higher script counts but steadier per-member spending because the pricing is now consistent across carriers. The updated prior authorization standard also levels the field: oral and nasal CGRP drugs get assessed under the same criteria as injectables like Aimovig and Emgality. That removes headaches, figuratively, at least, for doctors and patients alike.
2024 vs. 2025: Side-by-Side Requirements
| Category | 2024 Rules | 2025 Benchmark Update | Practical Outcome |
|---|---|---|---|
| Drug Tier Definitions | Varied by carrier, with optional threshold for specialty classification | Unified cost threshold of $670/dose for specialty classification | Some branded migraine drugs move out of Tier 4 |
| Rebate Transparency | Carrier-reporting optional | Mandatory rebate reporting to Covered California | Encourages re-tiering based on true net cost |
| Prior Authorization | Carrier discretion | Standardized across CGRP drug class | Streamlined access for patients |
| Benefit Design | Mix of coinsurance and copay | More fixed-dollar copays at preferred brand levels | Greater cost predictability for patients |
For Benefits Managers and Pharmacists
ACA plan benefits teams need to rebuild rebate modeling and member cost projections before open enrollment kicks off in October 2024. PBMs have some data syncing ahead to stay compliant with the new rebate disclosure rules. Pharmacists should double-check tier statuses in their lookup systems come December. Reclassification affects substitution options and how they counsel on refills. The point is straightforward: migraine drugs will soon behave more like standard preferred brands than specialty carve-outs.
And here’s the thing, California tends to set the tone. CMS often borrows from state marketplace policies when updating Qualified Health Plan standards nationwide. If this benchmark design works, expect similar rebating logic elsewhere by 2026. That’s not a prediction, that’s just how policy gravity works in health insurance.
Outlook for People Managing Migraine
Once these new tiers apply, migraine patients using CGRP inhibitors should see steadier, more predictable costs at the counter. It’s a sign that the therapy class has matured, insurers now recognize it as a mainstream option, not a boutique add-on. Anyone currently paying specialty-level coinsurance for Zavzpret or Qulipta will notice the shift starting January 1, 2025. Assuming, of course, their plan’s formulary keeps up with the benchmark. Most will.
Medical and Insurance Disclaimer: This article is for general informational purposes and doesn’t serve as medical advice, drug recommendation, or a guarantee of coverage. Patients should confirm their own benefit structures directly with their plan or pharmacist. Data references: CMS, Covered California Policy & Benefit Design Update (April 2024), DMHC filings, and KFF ACA marketplace analysis (2023).